This trial is testing a new combination therapy for metastatic melanoma. The therapy consists of anti-PD1 monoclonal antibodies and AV-MEL-1. The study is open to patients who have never received treatment for metastatic melanoma or who have been previously treated with anti-PD-1 or with inhibitors of the BRAF/MEK pathway. The trial will enroll 14 to 20 patients.
1 Primary · 0 Secondary · Reporting Duration: 3 years
20 Total Participants · 1 Treatment Group
Primary Treatment: AV-MEL-1 · No Placebo Group · Phase 1
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: